Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2028-10-28
Target enrollment:
Participant gender:
Summary
Isatuximab targets and kills CD38-positive myeloma cells in manner similar to rituximab's
mechanism of action on CD20-positive lymphoma cells. Based on the synergy between rituximab
and bendamustine, as well as the established clinical efficacy of bendamustine and isatuximab
as single agents for multiple myeloma, the logical next step is to combine isatuximab with
bendamustine and prednisone. Due to lack of effective therapies in refractory multiple
myeloma, herein the investigators propose studying this novel combination in this population,
in order to address a significant unmet need. The aim of the investigators is to first
determine the maximal tolerated dose of the combination in participants with
relapsed/refractory myeloma and then to establish the efficacy of this novel combination.